{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:38:55Z","timestamp":1792784335302,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Sir Charles Hercus Health Research","award":["3620187"],"award-info":[{"award-number":["3620187"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.neuropharm.2016.12.021","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T10:20:05Z","timestamp":1482488405000},"page":"233-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice"],"prefix":"10.1016","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8598-1535","authenticated-orcid":false,"given":"Ailsa L.","family":"McGregor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"D'Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm D.","family":"Tingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.neuropharm.2016.12.021_bib1","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bcp.2007.06.033","article-title":"Neuronal nicotinic receptors: a perspective on two decades of drug discovery research","volume":"74","author":"Arneric","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.expneurol.2011.12.013","article-title":"Protein aggregates in Huntington's disease","volume":"238","author":"Arrasate","year":"2012","journal-title":"Exp. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.12.021_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1385\/JMN:30:1:17","article-title":"Therapeutic potential of novel selective drugs targeting nicotinic acetylcholine receptors","volume":"30","author":"Bencherif","year":"2006","journal-title":"J.\u00a0Mol. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.12.021_bib5","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1124\/pr.113.008581","article-title":"Therapeutic potential of alpha 7 nicotinic acetylcholine receptors","volume":"67","author":"Bertrand","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.110.167213","article-title":"In\u00a0vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease","volume":"334","author":"Bitner","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.12.021_bib7","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1073\/pnas.0511256103","article-title":"Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases","volume":"103","author":"Bodner","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"26","key":"10.1016\/j.neuropharm.2016.12.021_bib8","doi-asserted-by":"crossref","first-page":"8734","DOI":"10.1523\/JNEUROSCI.0931-10.2010","article-title":"Endogenous signaling through alpha7-containing nicotinic receptors promotes maturation and integration of adult-born neurons in the hippocampus","volume":"30","author":"Campbell","year":"2010","journal-title":"J.\u00a0Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.12.021_bib9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.bcp.2011.06.021","article-title":"Nicotinic control of adult-born neuron fate","volume":"82","author":"Campbell","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib10","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1523\/JNEUROSCI.23-03-00961.2003","article-title":"Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease","volume":"23","author":"Cepeda","year":"2003","journal-title":"J.\u00a0Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib11","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neuropharm.2005.09.018","article-title":"alpha7 Nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in beta-amyloid infused rats","volume":"50","author":"Chen","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.12.021_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fnins.2013.00114","article-title":"Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility","volume":"7","author":"Chen","year":"2013","journal-title":"Front. Neurosci."},{"issue":"1-2","key":"10.1016\/j.neuropharm.2016.12.021_bib102","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00429-008-0181-5","article-title":"Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex","volume":"213","author":"Colantuoni","year":"2008","journal-title":"Brain Struct. Funct"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib13","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00213-005-0093-5","article-title":"Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment","volume":"182","author":"Cryan","year":"2005","journal-title":"Psychopharmacology"},{"issue":"4\u20135","key":"10.1016\/j.neuropharm.2016.12.021_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.neubiorev.2005.03.008","article-title":"Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1100\/tsw.2001.74","article-title":"Nicotinic receptor activity alters synaptic plasticity","volume":"1","author":"Dani","year":"2001","journal-title":"Sci. World J."},{"issue":"12","key":"10.1016\/j.neuropharm.2016.12.021_bib16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1002\/mds.20235","article-title":"Effects of rivastigmine on motor and cognitive impairment in Huntington's disease","volume":"19","author":"de Tommaso","year":"2004","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nprot.2006.2","article-title":"T-maze alternation in the rodent","volume":"1","author":"Deacon","year":"2006","journal-title":"Nat. Protoc."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.12.021_bib18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nrn2822","article-title":"New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?","volume":"11","author":"Deng","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"6\u20137","key":"10.1016\/j.neuropharm.2016.12.021_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.lfs.2012.12.013","article-title":"Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum\/diagonal band neurons","volume":"92","author":"DuBois","year":"2013","journal-title":"Life Sci."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.12.021_bib97","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.neuropharm.2012.08.012","article-title":"Allopregnanolone regulates neurogenesis and depressive\/anxiety-like behaviour in a social isolation rodent model of chronic stress","volume":"63","author":"Evans","year":"2012","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib20","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/1531-8257(200001)15:1<173::AID-MDS1032>3.0.CO;2-T","article-title":"Donepezil for Huntington's disease","volume":"15","author":"Fernandez","year":"2000","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2016.12.021_bib21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/FBP.0b013e32830c360e","article-title":"Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice","volume":"19","author":"Fowler","year":"2008","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.neuropharm.2012.08.004","article-title":"Effects of nicotinic acetylcholine receptor agonists on cognition in rhesus monkeys with a chronic cocaine self-administration history","volume":"64","author":"Gould","year":"2013","journal-title":"Neuropharmacology"},{"issue":"5","key":"10.1016\/j.neuropharm.2016.12.021_bib23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.neuron.2016.01.018","article-title":"Brain alpha7 nicotinic acetylcholine receptor assembly requires NACHO","volume":"89","author":"Gu","year":"2016","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.neuropharm.2016.12.021_bib24","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1111\/acer.12588","article-title":"Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization","volume":"38","author":"Gubner","year":"2014","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib25","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-319-13665-3_5","article-title":"Nicotinic receptors and attention","volume":"23","author":"Hahn","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib26","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1124\/jpet.105.090852","article-title":"Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons","volume":"315","author":"Hamada","year":"2005","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"12","key":"10.1016\/j.neuropharm.2016.12.021_bib27","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1111\/j.1460-9568.2007.05625.x","article-title":"AAV-mediated delivery of BDNF augments neurogenesis in the normal and quinolinic acid-lesioned adult rat brain","volume":"25","author":"Henry","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.12.021_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bcp.2006.08.010","article-title":"Partial agonists as therapeutic agents at neuronal nicotinic acetylcholine receptors","volume":"73","author":"Hogg","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib101","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mp.2012.174","article-title":"Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression","volume":"19","author":"Kunii","year":"2014","journal-title":"Mol. Psychiatry"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0896-6273(01)00332-4","article-title":"Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity","volume":"31","author":"Ji","year":"2001","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.neuropharm.2016.12.021_bib30","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1523\/JNEUROSCI.5687-08.2009","article-title":"Age-dependent alterations of corticostriatal activity in the YAC128 mouse model of Huntington disease","volume":"29","author":"Joshi","year":"2009","journal-title":"J.\u00a0Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.bbr.2011.04.012","article-title":"A\u00a0comparison of brain and behavioral effects of varenicline and nicotine in rats","volume":"223","author":"King","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib32","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-3-319-13665-3_6","article-title":"Nicotinic receptors, memory, and hippocampus","volume":"23","author":"Kutlu","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.bbr.2015.05.056","article-title":"Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairments","volume":"291","author":"Lambert","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib34","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neuropharm.2016.03.025","article-title":"Effects of varenicline on alpha4-containing nicotinic acetylcholine receptor expression and cognitive performance in mice","volume":"107","author":"Lange-Asschenfeldt","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2016.12.021_bib35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1756-6606-6-58","article-title":"alpha7nAchR\/NMDAR coupling affects NMDAR function and object recognition","volume":"6","author":"Li","year":"2013","journal-title":"Mol. Brain"},{"issue":"7","key":"10.1016\/j.neuropharm.2016.12.021_bib105","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.bcp.2009.06.004","article-title":"Nicotinic acetylcholine receptors and the ascending dopamine pathways","volume":"78","author":"Livingstone","year":"2009","journal-title":"Biochem. Pharmacol"},{"issue":"24","key":"10.1016\/j.neuropharm.2016.12.021_bib36","doi-asserted-by":"crossref","first-page":"9104","DOI":"10.1523\/JNEUROSCI.20-24-09104.2000","article-title":"Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus","volume":"20","author":"Malberg","year":"2000","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2015.07.019","article-title":"Chronic treatment with varenicline changes expression of four nAChR binding sites in mice","volume":"99","author":"Marks","year":"2015","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.neuropharm.2016.12.021_bib38","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1523\/JNEUROSCI.4320-04.2005","article-title":"Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice","volume":"25","author":"Mazarakis","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib104","series-title":"Varenicline improves motor and cognitive symptoms in the YAC128 transgenic mouse model of Huntington\u2019s Disease","author":"McGregor","year":"2014"},{"key":"10.1016\/j.neuropharm.2016.12.021_bib39","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.2147\/NDT.S111083","article-title":"Varenicline improves motor and cognitive symptoms in early Huntington's disease","volume":"12","author":"McGregor","year":"2016","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"5","key":"10.1016\/j.neuropharm.2016.12.021_bib103","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0197-4580(90)90115-G","article-title":"Quantitative analysis of age-related dendritic changes in medium spiny I (MSI) striatal neurons of C57BL\/6N mice","volume":"11","author":"McNeill","year":"1990","journal-title":"Neurobiol. Aging"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1124\/mol.106.025130","article-title":"Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors","volume":"70","author":"Mihalak","year":"2006","journal-title":"Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2016.12.021_bib41","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/hmg\/ddl092","article-title":"Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease","volume":"15","author":"Milnerwood","year":"2006","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib42","doi-asserted-by":"crossref","first-page":"h2388","DOI":"10.1136\/bmj.h2388","article-title":"Varenicline and risk of psychiatric conditions, suicidal behaviour, criminal offending, and transport accidents and offences: population based cohort study","volume":"350","author":"Molero","year":"2015","journal-title":"Bmj"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib43","first-page":"21","article-title":"Brain imaging and cognitive dysfunctions in Huntington's disease","volume":"31","author":"Montoya","year":"2006","journal-title":"J.\u00a0Psychiatry Neurosci. JPN"},{"key":"10.1016\/j.neuropharm.2016.12.021_bib44","series-title":"Acute Intermittent Nicotine Treatment Enhances Proliferation of Neuronal Precirsor Cells in the Subventricular Zone of Adult Rat Brain. National Congress of the Italian Society for Neuroscience and Joint Italian-swedish Neuroscience Meeting","first-page":"1","author":"Mudo","year":"2005"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00702-006-0561-z","article-title":"Nicotinic receptor agonists as neuroprotective\/neurotrophic drugs. Progress in molecular mechanisms","volume":"114","author":"Mudo","year":"2006","journal-title":"J.\u00a0Neural Transm (Vienna)."},{"issue":"13","key":"10.1016\/j.neuropharm.2016.12.021_bib46","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.1523\/JNEUROSCI.20-13-05115.2000","article-title":"Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation","volume":"20","author":"Murphy","year":"2000","journal-title":"J.\u00a0Neurosci."},{"issue":"Pt B","key":"10.1016\/j.neuropharm.2016.12.021_bib47","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuropharm.2014.10.021","article-title":"The nicotinic cholinergic system function in the human brain","volume":"96","author":"Nees","year":"2015","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib48","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1046\/j.0953-816X.2000.01379.x","article-title":"Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6\/1 Huntington transgenic mice","volume":"13","author":"Nicniocaill","year":"2001","journal-title":"Eur. J. Neurosci."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.12.021_bib49","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.euroneuro.2015.04.018","article-title":"Positive allosteric modulation of alpha 7 nicotinic acetylcholine receptors enhances recognition memory and cognitive flexibility in rats","volume":"25","author":"Nikiforuk","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib50","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/B978-0-12-381328-2.00013-4","article-title":"Huntington's disease: clinical presentation and treatment","volume":"98","author":"Novak","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib51","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1124\/dmd.105.006767","article-title":"Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in\u00a0vivo and in\u00a0vitro","volume":"34","author":"Obach","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib52","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.biopsych.2008.08.028","article-title":"Varenicline improves mood and cognition during smoking abstinence","volume":"65","author":"Patterson","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.neuropharm.2016.12.021_bib53","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/jnnp.50.6.806","article-title":"Nicotinic receptor abnormalities in Alzheimer's and Parkinson's diseases","volume":"50","author":"Perry","year":"1987","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"issue":"7","key":"10.1016\/j.neuropharm.2016.12.021_bib54","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.4088\/JCP.08m04441","article-title":"Varenicline augmentation in depressed smokers: an 8-week, open-label study","volume":"70","author":"Philip","year":"2009","journal-title":"J.\u00a0Clin. Psychiatry"},{"issue":"11","key":"10.1016\/j.neuropharm.2016.12.021_bib55","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington's disease","volume":"23","author":"Phillips","year":"2008","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib56","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0006-8993(91)91734-I","article-title":"[3H]nitrendipine binding in temporal cortex in Alzheimer's and Huntington's diseases","volume":"565","author":"Piggott","year":"1991","journal-title":"Brain Res."},{"issue":"21","key":"10.1016\/j.neuropharm.2016.12.021_bib57","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1111\/bph.13277","article-title":"Pro-cognitive activity in rats of 3-furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the alpha7 nicotinic acetylcholine receptor","volume":"172","author":"Potasiewicz","year":"2015","journal-title":"Br. J. Pharmacol."},{"issue":"17","key":"10.1016\/j.neuropharm.2016.12.021_bib58","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1523\/JNEUROSCI.0215-06.2006","article-title":"Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates","volume":"26","author":"Quik","year":"2006","journal-title":"J.\u00a0Neurosci."},{"issue":"12","key":"10.1016\/j.neuropharm.2016.12.021_bib100","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1517\/14728222.11.12.1649","article-title":"Is DARPP-32 a potential therapeutic target?","volume":"11","author":"Reis","year":"2007","journal-title":"Expert Opin Ther Targ."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1478-811X-7-20","article-title":"Cholinergic receptor pathways involved in apoptosis, cell proliferation and neuronal differentiation","volume":"7","author":"Resende","year":"2009","journal-title":"Cell Commun. Signal"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib60","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.neuropharm.2006.10.016","article-title":"Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid","volume":"52","author":"Rollema","year":"2007","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2016.12.021_bib61","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejphar.2009.01.002","article-title":"Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect","volume":"605","author":"Rollema","year":"2009","journal-title":"Eur. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.12.021_bib62","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.bcp.2009.05.033","article-title":"Preclinical pharmacology of the alpha4beta2 nAChR partial agonist varenicline related to effects on reward, mood and cognition","volume":"78","author":"Rollema","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.12.021_bib63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1046\/j.1468-1331.2002.00447_4.x","article-title":"Rivastigmine in the treatment of Huntington's disease","volume":"9","author":"Rot","year":"2002","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.12.021_bib64","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1007\/s00702-005-0370-2","article-title":"Effects of nicotine on neurogenesis and plasticity of hippocampal neurons","volume":"112","author":"Shingo","year":"2005","journal-title":"J.\u00a0Neural Transm."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib65","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nbd.2010.09.012","article-title":"Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease","volume":"41","author":"Simpson","year":"2011","journal-title":"Neurobiol. Dis."},{"issue":"13","key":"10.1016\/j.neuropharm.2016.12.021_bib66","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib67","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddl252","article-title":"Cholinergic neuronal defect without cell loss in Huntington's disease","author":"Smith","year":"2006","journal-title":"Hum. Mol. Genet."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2016.12.021_bib68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.schres.2009.02.001","article-title":"Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder","volume":"110","author":"Smith","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib69","doi-asserted-by":"crossref","first-page":"e0143490","DOI":"10.1371\/journal.pone.0143490","article-title":"Varenicline effects on smoking, cognition, and psychiatric symptoms in schizophrenia: a double-blind randomized trial","volume":"11","author":"Smith","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib70","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/brain\/103.1.179","article-title":"Neurochemical alterations in Huntington's chorea: a study of post-mortem brain tissue","volume":"103","author":"Spokes","year":"1980","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neuropharm.2016.12.021_bib72","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1085\/jgp.201010532","article-title":"Nicotine up-regulates alpha4beta2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning","volume":"137","author":"Srinivasan","year":"2011","journal-title":"J.\u00a0Gen. Physiol."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.12.021_bib73","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/mol.112.077792","article-title":"Pharmacological chaperoning of nicotinic acetylcholine receptors reduces the endoplasmic reticulum stress response","volume":"81","author":"Srinivasan","year":"2012","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib74","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.phrs.2014.02.005","article-title":"Pharmacological chaperoning of nAChRs: a therapeutic target for Parkinson's disease","volume":"83","author":"Srinivasan","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib99","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.neuroscience.2016.07.022","article-title":"Human t-DARPP is induced during striatal development","volume":"333","author":"Straccia","year":"2016","journal-title":"Neuroscience"},{"issue":"5932","key":"10.1016\/j.neuropharm.2016.12.021_bib75","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1126\/science.1172871","article-title":"Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity","volume":"324","author":"Subramaniam","year":"2009","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.12.021_bib76","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/syn.1089","article-title":"Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers","volume":"41","author":"Suzuki","year":"2001","journal-title":"Synapse"},{"issue":"30","key":"10.1016\/j.neuropharm.2016.12.021_bib77","doi-asserted-by":"crossref","first-page":"7899","DOI":"10.1523\/JNEUROSCI.1396-07.2007","article-title":"Dopaminergic signaling and striatal neurodegeneration in Huntington's disease","volume":"27","author":"Tang","year":"2007","journal-title":"J.\u00a0Neurosci."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2016.12.021_bib78","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.brainresbull.2005.06.024","article-title":"Neuroprotective effect of nicotine against 3-nitropropionic acid (3-NP)-induced experimental Huntington's disease in rats","volume":"67","author":"Tariq","year":"2005","journal-title":"Brain Res. Bull."},{"issue":"7","key":"10.1016\/j.neuropharm.2016.12.021_bib79","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.2174\/1871527313666140917121132","article-title":"Cholinergic system dysfunction and neurodegenerative diseases: cause or effect?","volume":"13","author":"Tata","year":"2014","journal-title":"CNS Neurol. Disord. Drug Targ."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib80","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.neuroscience.2004.04.061","article-title":"Neurogenesis in the striatum of the quinolinic acid lesion model of Huntington's disease","volume":"127","author":"Tattersfield","year":"2004","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.neuropharm.2016.12.021_bib81","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.bcp.2015.07.027","article-title":"Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders","volume":"97","author":"Terry","year":"2015","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib82","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1124\/jpet.110.166280","article-title":"Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior","volume":"334","author":"Turner","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2016.12.021_bib83","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/jnp.2007.19.4.441","article-title":"Psychopathology in verified Huntington's disease gene carriers","volume":"19","author":"van Duijn","year":"2007","journal-title":"J.\u00a0Neuropsychiatry Clin. Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2016.12.021_bib84","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.4088\/JCP.v69n1116","article-title":"Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington's disease compared with mutation-negative first-degree relatives","volume":"69","author":"van Duijn","year":"2008","journal-title":"J.\u00a0Clin. Psychiatry"},{"issue":"16","key":"10.1016\/j.neuropharm.2016.12.021_bib85","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1523\/JNEUROSCI.0590-05.2005","article-title":"Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease","volume":"25","author":"Van Raamsdonk","year":"2005","journal-title":"J.\u00a0Neurosci."},{"issue":"24","key":"10.1016\/j.neuropharm.2016.12.021_bib86","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/hmg\/ddi407","article-title":"Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease","volume":"14","author":"Van Raamsdonk","year":"2005","journal-title":"Hum. Mol. Genet."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib87","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.expneurol.2006.01.034","article-title":"Transplanted adult neural progenitor cells survive, differentiate and reduce motor function impairment in a rodent model of Huntington's disease","volume":"199","author":"Vazey","year":"2006","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib98","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nmeth741","article-title":"Stem cell proliferative history in tissue revealed by temporal halogenated thymidine analog discrimination","volume":"2","author":"Vega","year":"2005","journal-title":"Nat. Methods"},{"key":"10.1016\/j.neuropharm.2016.12.021_bib88","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/7854_2014_354","article-title":"The neuropathology of Huntington's disease","volume":"22","author":"Waldvogel","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.neuropharm.2016.12.021_bib89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuropharm.2013.05.016","article-title":"Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia","volume":"73","author":"Wecker","year":"2013","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib90","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hipo.20163","article-title":"Inhibition of neurogenesis interferes with hippocampus-dependent memory function","volume":"16","author":"Winocur","year":"2006","journal-title":"Hippocampus"},{"issue":"11","key":"10.1016\/j.neuropharm.2016.12.021_bib91","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/ntr\/nts091","article-title":"Nicotinic ACh receptors in the hippocampus: role in excitability and plasticity","volume":"14","author":"Yakel","year":"2012","journal-title":"Nicotine Tob. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2016.12.021_bib92","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/jpet.113.211706","article-title":"Activation of alpha4beta2*\/alpha6beta2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors","volume":"349","author":"Yohn","year":"2014","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.neuropharm.2016.12.021_bib93","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/mds.25762","article-title":"Executive functions in premanifest Huntington's disease","volume":"29","author":"You","year":"2014","journal-title":"Mov. Disord. Off. J. Mov. Disord. Soc."},{"issue":"1\u20133","key":"10.1016\/j.neuropharm.2016.12.021_bib94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0378-4274(01)00502-1","article-title":"Nicotine and neurodegeneration in ageing","volume":"127","author":"Zanardi","year":"2002","journal-title":"Toxicol. Lett."},{"issue":"6","key":"10.1016\/j.neuropharm.2016.12.021_bib95","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/WNF.0b013e31818736a9","article-title":"Treatment of ataxia and imbalance with varenicline (chantix): report of 2 patients with spinocerebellar ataxia (types 3 and 14)","volume":"31","author":"Zesiewicz","year":"2008","journal-title":"Clin. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.neuropharm.2016.12.021_bib96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/WNL.0b013e318247cc7a","article-title":"A\u00a0randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3","volume":"78","author":"Zesiewicz","year":"2012","journal-title":"Neurology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081630586X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839081630586X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T17:48:35Z","timestamp":1568656115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839081630586X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":103,"alternative-id":["S002839081630586X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.12.021","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Varenicline improves motor and cognitive deficits and decreases depressive-like behaviour in late-stage YAC128 mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2016.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}